Lipid Profile in Thalassemia Major Patients on Desferrioxamine  Therapy

A. Al-Kataan, Mohammad; A. Zainal, Adnan

	Lipid Profile in Thalassemia Major Patients on Desferrioxamine Therapy
Medical Journal of Babylon
Article 1, Volume 6, Issue 2, 2009, Pages 358-365
Authors
Mohammad A. Al-Kataan; Adnan A. Zainal
Abstract
Objectives: (a) To determine the differences in lipid profile parameters between thalassemia major (TM) patients not taking desferroxamine (DFO) who show signs of iron overload (IOL) and those well-controlled TM patients on DFO therapy. (b) To determine the effects of age and BMI on measured parameters in both groups. Subjects and Methods: The study was conducted in Thalassemia Center at Ibn-Al-Atheer Pediatric Hospital in Mosul from October 2007 to April 2008. Twenty patients with TM were selected as follows: Ten patients on DFO therapy with no signs of IOL and ten TM patients not on DFO therapy and showing signs of IOL. Data were presented as mean ± SD; independent samples t-test was used in comparing both groups, while effects of age and BMI on measured parameters were determined by using Pearson correlation. Results: Total cholesterol (TC), triglyceride (TG), Very low density lipoprotein (VLDL-C), low density lipoprotein (LDL-C) and atherogenic index (AI) showed significant increase in IOL group, while serum high density lipoprotein (HDL-C) showed significant reduction in IOL group, when compared to the second group. Age and BMI show no significant correlation with measured parameters in well-controlled group, while in IOL group, BMI showed positive correlation with LDL-C and AI. Conclusion: Significant changes in lipid profile parameters were seen in TM patients not taking DFO therapy and showing signs of IOL compared to those well-controlled patients on DFO therapy.

Statistics Article View: 205 PDF Download: 187